Incidence and survival of gynecologic cancer including cervical, uterine, ovarian, vaginal, vulvar cancer and gestational trophoblastic neoplasia in Korea, 1999-2019: Korea Central Cancer Registry
2
조회
0
다운로드
5
인용
0
참고문헌
키워드
초록
Objective To investigate the incidence, trends, and survival rates of all gynecologic cancers using the Korea Central Cancer Registry (KCCR) database from 1999-2019. Methods Gynecologic cancer data were obtained from the KCCR database between 1999 and 2019. Age-standardized incidence rates (ASRs), annual percentage changes, and average annual percentage changes (AAPCs) were calculated. The relative survival rate (RSR) was reported by age group, stage, and 6-year period (I: 1999-2005, II: 2006-2012, III: 2013- 2019). Results The gynecologic cancer ASRs were 26.2 and 24.9 per 100,000 individuals in 1999 and 2019, respectively. Trends of incidence in gynecologic cancer revealed a decrease in cervical cancer and gestational trophoblastic neoplasia (GTN) with AAPCs of -3.4 and -4.3, respectively. Conversely, the incidence of uterine, ovarian, and vulvar cancers increased with AAPCs of 4.7, 2.3, and 2.1, respectively. AAPC for vaginal cancer showed no change. The 5-year survival rate was highest for GTN (90.5%) and lowest for vaginal cancer (56.6%). An increase in age was correlated with poorer survival rates across all gynecologic cancers, excluding vaginal cancer. For all gynecologic cancer types, the prognosis deteriorates with advancing cancer stages. The RSR of uterine cancer improved consistently across all periods. The ovarian cancer RSR improved more in period III than in periods I or II. Additionally, the vulvar cancer RSR improved more in periods II and III than in period I. Conclusion In Korea, the incidence of cervical cancer and GTN decreased, whereas the incidence of uterine, ovarian, and vulvar cancer increased from 1999 to 2019. The RSR for uterine, ovarian, and vulvar cancers showed consistent improvements over different periods. Effective screening programs and the adoption of advanced treatments may be necessary to further reduce the burden of gynecologic cancer.
Abstract
Objective To investigate the incidence, trends, and survival rates of all gynecologic cancers using the Korea Central Cancer Registry (KCCR) database from 1999-2019. Methods Gynecologic cancer data were obtained from the KCCR database between 1999 and 2019. Age-standardized incidence rates (ASRs), annual percentage changes, and average annual percentage changes (AAPCs) were calculated. The relative survival rate (RSR) was reported by age group, stage, and 6-year period (I: 1999-2005, II: 2006-2012, III: 2013- 2019). Results The gynecologic cancer ASRs were 26.2 and 24.9 per 100,000 individuals in 1999 and 2019, respectively. Trends of incidence in gynecologic cancer revealed a decrease in cervical cancer and gestational trophoblastic neoplasia (GTN) with AAPCs of -3.4 and -4.3, respectively. Conversely, the incidence of uterine, ovarian, and vulvar cancers increased with AAPCs of 4.7, 2.3, and 2.1, respectively. AAPC for vaginal cancer showed no change. The 5-year survival rate was highest for GTN (90.5%) and lowest for vaginal cancer (56.6%). An increase in age was correlated with poorer survival rates across all gynecologic cancers, excluding vaginal cancer. For all gynecologic cancer types, the prognosis deteriorates with advancing cancer stages. The RSR of uterine cancer improved consistently across all periods. The ovarian cancer RSR improved more in period III than in periods I or II. Additionally, the vulvar cancer RSR improved more in periods II and III than in period I. Conclusion In Korea, the incidence of cervical cancer and GTN decreased, whereas the incidence of uterine, ovarian, and vulvar cancer increased from 1999 to 2019. The RSR for uterine, ovarian, and vulvar cancers showed consistent improvements over different periods. Effective screening programs and the adoption of advanced treatments may be necessary to further reduce the burden of gynecologic cancer.
참고문헌 (38)
- Sung H, "Global cancer statistics 2020 : GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries", CA Cancer J Clin, 71, pp.209~249 (2021)
- "Annual report on the causes of death statistics" (2020)[URL]
- 강미주, "Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2020", Cancer Research and Treatment, 55(2), pp.385~399 (2023), 대한암학회[DOI]
- 임명철, "Incidence of cervical, endometrial, and ovarian cancer in Korea during 1999–2015", Journal of Gynecologic Oncology, 30(1), pp.1~8 (2019), 대한부인종양학회[DOI]
- 하형인, "The incidence and survival of cervical, ovarian, and endometrial cancer in Korea, 1999-2017: Korea Central Cancer Registry", Obstetrics & Gynecology Science, 64(5), pp.444~453 (2021), 대한산부인과학회
- 신원교, "Incidence trends for epithelial peritoneal, ovarian, and fallopian tube cancer during 1999–2016: a retrospective study based on the Korean National Cancer Incidence Database", Journal of Gynecologic Oncology, 31(4), pp.1~9 (2020), 대한부인종양학회[DOI]
- Fritz A, "International classification of diseases for oncology" (2013), World Health Organization
- Young JL Jr, "SEER summary staging manual 2000: codes and coding instructions", pp.4969~ (2001), National Cancer Institute
- "ICD-10: international statistical classification of diseases and related health problems" (2010)[URL]
- Matz M, "The histology of ovarian cancer : worldwide distribution and implications for international survival comparisons(CONCORD-2)", Gynecol Oncol, 144, pp.405~413 (2017)
- Segi M, "Cancer mortality for selected sites in 24 countries (1950-1957)" (1960), Tohoku University School of Medicine
- Kim HJ, "Permutation tests for joinpoint regression with applications to cancer rates", Stat Med, 19, pp.335~351 (2000)
- Ederer F, "Instructions to IBM 650 programmers in processing survival computations" (1959), National Cancer Institute
- "Strs - estimating and modelling relative/net survival" (2016)[URL]
- 심승혁, "Nationwide cervical cancer screening in Korea: data from the National Health Insurance Service Cancer Screening Program and National Cancer Screening Program, 2009–2014", Journal of Gynecologic Oncology, 28(5), pp.1~12 (2017), 대한부인종양학회[DOI]
- 김영탁, "Current status of cervical cancer and HPV infection in Korea", Journal of Gynecologic Oncology, 20(1), pp.1~7 (2009), 대한부인종양학회
- Oh CM, "Trends in the incidence of in situ and invasive cervical cancer by age group and histological type in Korea from 1993 to 2009", PLoS One, 8, pp.e72012~ (2013)
- Gravdal BH, "Cervical cancer in women under 30 years of age in Norway : a population-based cohort study", BMC Womens Health, 21, pp.110~ (2021)
- Castanon A, "Characteristics and screening history of women diagnosed with cervical cancer aged 20-29 years", Br J Cancer, 109, pp.35~41 (2013)
- Raglan O, "Risk factors for endometrial cancer : an umbrella review of the literature", Int J Cancer, 145, pp.1719~1730 (2019)
- Jo H, "Metabolic syndrome as a risk factor of endometrial cancer : a nationwide population-based cohort study of 2. 8 million women in South Korea", Front Oncol, 12, pp.872995~ (2022)
- Kim JH, "Prevalence trends of metabolic syndrome among Korean children and adolescents from a population-based cross-sectional survey", Life(Basel), 12, pp.1404~ (2022)
- "Birth statistics in 2022" (2023)[URL]
- Kato H, "Macro-econometric analysis on determinants of fertility behavior", pp.51~76 (2021), Springer
- Chang SJ, "Para-aortic lymphadenectomy improves survival in patients with intermediate to high-risk endometrial carcinoma", Acta Obstet Gynecol Scand, 87, pp.1361~1369 (2008)
- Gordhandas S, "Current evidence-based systemic therapy for advanced and recurrent endometrial cancer", J Natl Compr Canc Netw, 21, pp.217~226 (2023)
- de Boer SM, "Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer(PORTEC-3) : final results of an international, open-label, multicentre, randomised, phase 3trial", Lancet Oncol, 19, pp.295~309 (2018)
- Yagi A, "Improved long-term survival of corpus cancer in Japan : a 40-year population-based analysis", Int J Cancer, 150, pp.232~242 (2022)
- Park M, "Incidence and outcomes of malignant ovarian germ cell tumors in Korea, 1999-2017", Gynecol Oncol, 163, pp.79~84 (2021)
- Doubeni CA, "Diagnosis and management of ovarian cancer", Am Fam Physician, 93, pp.937~944 (2016)
- Chang SJ, "Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer", Ann Surg Oncol, 19, pp.4059~4067 (2012)
- Perren TJ, "A phase 3 trial of bevacizumab in ovarian cancer", N Engl J Med, 365, pp.2484~2496 (2011)
- Moore K, "Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer", N Engl J Med, 379, pp.2495~2505 (2018)
- Chen W, "Disparities by province, age, and sex in site-specific cancer burden attributable to 23 potentially modifiable risk factors in China : a comparative risk assessment", Lancet Glob Health, 7, pp.e257~69 (2019)
- Lai J, "Vulval cancer incidence, mortality and survival in England : age-related trends", BJOG, 121, pp.728~738 (2014)
- Meltzer-Gunnes CJ, "Vulvar carcinoma in Norway : a 50-year perspective on trends in incidence, treatment and survival", Gynecol Oncol, 145, pp.543~548 (2017)
- Trétarre B, "Trends in incidence of invasive vaginal cancer in France from 1990 to 2018 and survival of recently diagnosed women-a population-based study", Eur J Obstet Gynecol Reprod Biol, 283, pp.125~129 (2023)
- Gadducci A, "Prognosis of patients with gestational trophoblastic neoplasia and obstetric outcomes of those conceiving after chemotherapy", Anticancer Res, 36, pp.3477~3482 (2016)